2026-07-02

JTO/JitoSOL has $819.9M 24h volume on $1689K liquidity (485x turnover): thin market, elevated slippage

SOL open interest +222.7% - OI surge

ETH open interest -68.2% - OI collapse

BTC open interest +237.3% - OI surge

BTC ETF outflow of $2272M - institutional selling

ETH ETF outflow of $226M - institutional selling

ETH open interest +207.0% - OI surge

SOL open interest -56.3% - OI collapse

BTC open interest +236.5% - OI surge

SOL open interest -57.4% - OI collapse

BTC open interest +241.0% - OI surge

ETH open interest +210.5% - OI surge

ETH ETF outflow of $226M - institutional selling

ETH open interest -67.8% - OI collapse

SOL open interest -58.4% - OI collapse

BTC open interest -70.1% - OI collapse

ETH DEX volume/liquidity ratio elevated (0.50x): on-chain trade volume 0.50x liquidity

SOL DEX volume/liquidity ratio elevated (5.09x): on-chain trade volume 5.09x liquidity

SOL RSI 70.1 - overbought (crossed above 70)

SOL DEX volume/liquidity ratio elevated (1.93x): on-chain trade volume 1.93x liquidity

SOL RSI 70.3 - overbought (crossed above 70)

BITCOIN - speculators net long (+2.5σ vs 52w mean) - contrarian bear signal

SOL DEX volume/liquidity ratio elevated (4.63x): on-chain trade volume 4.63x liquidity

Coffee bear 6.8% vs prior close ($324.30 → $302.15)

Coffee volume spike - 2.7× the 20-day average (27,600 vs 10,231 avg)

OSINT: Israeli Threats to Iranian Leaders Spark Tension as Iran Claims Pakistani Escort

OSINT: Hassett flags Powell's Fed tenure as unusual

OSINT: Solana tops blockchain for tokenized RWAs, $3.4B value hits record

OSINT: Trump backs Freedom Fuel Network's price cuts at 25 NE stations

Cotton bull 5.8% vs prior close ($73.28 → $77.52)

Corn bull 4.7% vs prior close ($421.00 → $440.75)

Gold +1.61%: significant gain on the session

Oil -1.46%: significant decline on the session

Gold +2.05%: significant gain on the session

Oil -1.57%: significant decline on the session

Ukraine Black Sea Belt: crop water stress detected (2.4σ above baseline) - potential ZW=F supply pressure

OSINT: Russia bans gasoline exports, tightening global fuel supply

OSINT: Ukrainian drones strike Russia's Kstovo oil refinery, igniting unit

Oil -2.66%: significant decline on the session

Gold +1.05%: significant gain on the session

Phase 3 trial terminated early - ELI A Study in Participants With Rheumatoid Arthritis

Phase 3 trial terminated early - ELI Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty A

Phase 3 trial terminated early - BIOGEN Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improv

Phase 3 trial terminated early - AMGEN Reducing Intracranial atheroSclErosis With Repatha

Phase 3 trial terminated early - Medtronic CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Sufferin

Phase 3 trial terminated early - AbbVie A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line

Phase 3 trial terminated early - Merck An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Pati

Phase 3 trial terminated early - Merck A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Comp

Phase 3 trial terminated early - Merck Study Comparing Cubicin With Vancomycin in Treatment of Participants With Compli

Phase 3 trial terminated early - PFIZER Acute Cough Study In Children

Phase 3 trial terminated early - PFIZER A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer

Phase 3 trial terminated early - ABBOTT Cardiac and Renal Biomarkers in Arthroplasty Surgery

Phase 3 trial terminated early - ABBOTT Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyro

Phase 3 trial terminated early - JOHNSON Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)

Phase 3 trial terminated early - ELI A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Ear

Phase 3 trial terminated early - ELI Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Phase 3 trial terminated early - Medtronic Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients

Phase 3 trial terminated early - AbbVie BOTOX Effects on Seizure Severity and Susceptibility

Phase 3 trial terminated early - Merck The Dublin Zepatier Study

Phase 3 trial terminated early - Merck A Study of MK0364 in Obese Patients (0364-014)

Phase 3 trial terminated early - PFIZER Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defin

Phase 3 trial terminated early - PFIZER Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photo

Phase 3 trial terminated early - PFIZER Parecoxib In Post Surgery (Hemicolectomy) Pain

Phase 3 trial terminated early - PFIZER Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Ac

Phase 3 trial terminated early - GILEAD Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and

S&P 500 MINI - speculators net long (+2.8σ vs 52w mean) - contrarian bear signal

Bank OZK search volume spiked +32 pts - unusual interest

RH search volume spiked +28 pts - unusual interest

TAL Education Group search volume spiked +100 pts - unusual interest

ABBOTT LABORATORIES search volume spiked +92 pts - unusual interest

Strategy Inc search volume spiked +33 pts - unusual interest

Bank OZK search volume spiked +32 pts - unusual interest

TAL Education Group search volume spiked +100 pts - unusual interest

ABBOTT LABORATORIES search volume spiked +92 pts - unusual interest

Q2-2026: Beat consensus by 6.6% - EPS $1.62 vs $1.519 estimate

Q3-2026: Beat consensus by 17.3% - EPS $25.11 vs $21.4019 estimate

Strategy Inc search volume spiked +33 pts - unusual interest

Bank OZK search volume spiked +32 pts - unusual interest

Q1-2026: Beat consensus by 11.0% - EPS $2.09 vs $1.883 estimate

TAL Education Group search volume spiked +100 pts - unusual interest

Q3-2026: Beat consensus by 12.3% - EPS $1.43 vs $1.2739 estimate

Q4-2025: Missed consensus by 131.7% - EPS $-2.44 vs $-1.053 estimate

Q4-2024: Missed consensus by 8.9% - EPS $1.5 vs $1.6463 estimate

Q3-2025: Beat consensus by 92.1% - EPS $0.44 vs $0.229 estimate

Q1-2016: Missed consensus by 197.0% - EPS $-1.2 vs $-0.404 estimate

Q1-2026: Missed consensus by 41.2% - EPS $0.12 vs $0.204 estimate

Q2-2025: Beat consensus by 20.2% - EPS $0.47 vs $0.391 estimate

Q3-2024: Beat consensus by 37.5% - EPS $-61.5 vs $-98.43 estimate

Q1-2025: Beat consensus by 37.8% - EPS $-13 vs $-20.91 estimate

Q4-2024: Missed consensus by 189.1% - EPS $-57.5 vs $-19.89 estimate

Q1-2026: Missed consensus by 179.2% - EPS $-0.08 vs $0.101 estimate

Q3-2026: Beat consensus by 18.8% - EPS $0.24 vs $0.202 estimate

Q3-2023: Beat consensus by 19.3% - EPS $-2304 vs $-2856 estimate

Q4-2023: Beat consensus by 74.5% - EPS $-304 vs $-1191.36 estimate

Q1-2026: Beat consensus by 37.3% - EPS $3.7 vs $2.694 estimate

Q4-2025: Beat consensus by 10.2% - EPS $2.51 vs $2.277 estimate

Q1-2026: Missed consensus by 5169.1% - EPS $-3.72 vs $-0.0706 estimate

Q2-2021: Beat consensus by 83.4% - EPS $-0.231 vs $-1.3939 estimate

Q1-2026: Beat consensus by 14.2% - EPS $0.33 vs $0.289 estimate

Q3-2025: Beat consensus by 23.3% - EPS $0.28 vs $0.227 estimate

Q2-2025: Beat consensus by 53.8% - EPS $0.18 vs $0.117 estimate

Q1-2026: Missed consensus by 335.3% - EPS $-0.24 vs $0.102 estimate

Q4-2025: Beat consensus by 68.4% - EPS $0.64 vs $0.38 estimate

Q2-2025: Missed consensus by 24.8% - EPS $0.36 vs $0.479 estimate

Q1-2026: Beat consensus by 10.9% - EPS $-0.2 vs $-0.2244 estimate

Q3-2022: Missed consensus by 786.3% - EPS $-266 vs $38.76 estimate

Q2-2022: Beat consensus by 167.9% - EPS $342 vs $-503.88 estimate

Q1-2026: Beat consensus by 16.0% - EPS $-0.3 vs $-0.357 estimate

Q4-2025: Missed consensus by 23.1% - EPS $0.17 vs $0.221 estimate

Q3-2025: Beat consensus by 98.5% - EPS $0.81 vs $0.408 estimate

Q4-2025: Missed consensus by 24.6% - EPS $0.5 vs $0.663 estimate

Q4-2025: Missed consensus by 34.6% - EPS $0.06 vs $0.0918 estimate

Q3-2025: Missed consensus by 176.3% - EPS $-0.07 vs $0.0918 estimate

Q2-2025: Missed consensus by 8.4% - EPS $0.32 vs $0.3492 estimate

Q1-2026: Beat consensus by 40.5% - EPS $0.6 vs $0.427 estimate

Q4-2026: Beat consensus by 7.3% - EPS $0.61 vs $0.5684 estimate

Q3-2025: Beat consensus by 9.5% - EPS $1.62 vs $1.48 estimate

Q1-2026: Beat consensus by 15.7% - EPS $3.87 vs $3.345 estimate

Q1-2026: Beat consensus by 32.9% - EPS $-0.13 vs $-0.1938 estimate

Q4-2025: Missed consensus by 90.6% - EPS $-0.35 vs $-0.1836 estimate

Q2-2025: Beat consensus by 19.4% - EPS $4.2 vs $3.519 estimate

Q3-2025: Missed consensus by 5.7% - EPS $4.23 vs $4.488 estimate

Q4-2025: Beat consensus by 32.4% - EPS $0.27 vs $0.204 estimate

Q3-2025: Missed consensus by 43.9% - EPS $0.27 vs $0.481 estimate

Q3-2026: Missed consensus by 56.9% - EPS $-0.08 vs $-0.051 estimate

Q1-2026: Missed consensus by 10.3% - EPS $-0.09 vs $-0.0816 estimate

Q1-2026: Beat consensus by 13.4% - EPS $6.42 vs $5.661 estimate

Beat consensus by 35.5% - EPS $-0.08 vs $-0.1241 estimate

Q1-2026: Beat consensus by 217.6% - EPS $0.27 vs $-0.2295 estimate

Q3-2025: Beat consensus by 5.4% - EPS $-0.21 vs $-0.2219 estimate

Q4-2025: Beat consensus by 56.5% - EPS $-0.09 vs $-0.2069 estimate

Q3-2025: Beat consensus by 32.4% - EPS $0.09 vs $0.068 estimate

Q4-2026: Missed consensus by 51.5% - EPS $-0.17 vs $-0.1122 estimate

Q4-2025: Beat consensus by 80.4% - EPS $-0.06 vs $-0.306 estimate

Q2-2025: Beat consensus by 26.5% - EPS $-0.3 vs $-0.408 estimate

Q3-2025: Beat consensus by 26.5% - EPS $-0.3 vs $-0.408 estimate

Q3-2025: Beat consensus by 115.7% - EPS $0.11 vs $0.051 estimate

Q1-2026: Missed consensus by 21.4% - EPS $-0.42 vs $-0.3461 estimate

Q4-2025: Beat consensus by 28.6% - EPS $-0.44 vs $-0.6165 estimate

Q1-2026: Beat consensus by 18.8% - EPS $0.12 vs $0.101 estimate

Q4-2025: Beat consensus by 14.9% - EPS $-0.4 vs $-0.4702 estimate

Q2-2025: Beat consensus by 10.3% - EPS $0.44 vs $0.399 estimate

Q1-2026: Missed consensus by 5.2% - EPS $7.54 vs $7.952 estimate

Q3-2025: Beat consensus by 6.2% - EPS $0.62 vs $0.584 estimate

Q4-2025: Beat consensus by 6.0% - EPS $-0.211 vs $-0.2244 estimate

ABBOTT LABORATORIES search volume spiked +92 pts - unusual interest

Strategy Inc search volume spiked +33 pts - unusual interest

Bank OZK search volume spiked +32 pts - unusual interest

TAL Education Group search volume spiked +100 pts - unusual interest

Southwest Gas Holdings, Inc. search volume spiked +100 pts - unusual interest

ABBOTT LABORATORIES search volume spiked +92 pts - unusual interest

Strategy Inc search volume spiked +45 pts - unusual interest

Q4-2025: EPS $-0.01 vs $-0.017 estimate, +0.01 on a near-zero consensus

Q1-2025: EPS $0.00 vs $-0.0206 estimate, +0.02 on a near-zero consensus

Q2-2025: EPS $0.001 vs $0.0102 estimate, -0.01 on a near-zero consensus

Q3-2025: EPS $0.00 vs $0.0102 estimate, -0.01 on a near-zero consensus

Q1-2025: EPS $-0.13 vs $-0.0408 estimate, -0.09 on a near-zero consensus

DXY -0.53% - dollar weakness signal

DXY -0.63% - dollar weakness signal

DXY -0.40% - dollar weakness signal

OSINT: Russia bans gasoline exports, tightening global fuel supply

OSINT: Ukrainian drones strike Russia's Kstovo oil refinery, igniting unit

OSINT: Russia bans gasoline exports, tightening global fuel supply

Financial conditions loosening: NFCI at -0.50, liquidity supportive